As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is ...

Before treatment, patients need a diagnosis confirmed ... based on a blood test as the enrolment criterion for dementia drug trials. That could pave the way for those blood tests, which look ...

Previous research has associated sleep medications with other health risks, such as falls, fractures, car accidents, and ...

Dementia with Lewy bodies (DLB ... health records of over 600,000 men who were taking different types of drug treatment for benign prostatic hyperplasia (BPH). Subjects were followed for an ...

Just 2.1 per cent of people with dementia undergo specialist investigations – such as having MRI or PET scans, which would be required for treatment with the breakthrough drugs lecanemab and ...

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study, out today in ...

(“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s ty ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...